Progenics Follow Verify

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.

http://www.progenics.com
Type	Public
Founded	1988
Headquarters	New York, New York
Number of employees	51-200 employees

Top 5 Recent Tweets

Date	Author	Comment
March 31, 2023	urotoday	#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene… https://t.co/BJFJ75rbGp
March 30, 2023	urotoday	#TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal… https://t.co/Mkr6UuP7Nq

Top 5 Lifetime News Headlines

Top Authors

• Cherry Ann Baluyut
• Chithma Kalansuriya
• Afaf Abdallah
• View all authors

Verification history

• 1,306 days ago


• 1,577 days ago


• 1,577 days ago


• View all verifications